DAAs Rapidly Reduce Inflammation but Increase Serum VEGF Level: A Rationale for Tumor Risk during Anti-HCV Treatment.

Novel direct-acting antivirals (DAAs) have completely changed the panorama of hepatitis C due to their high efficacy and optimal safety profile. Unfortunately, an unexpectedly high rate of early recurrence of hepatocellular carcinoma has been reported within weeks of starting treatment, but the mech...

Full description

Bibliographic Details
Main Authors: Rosanna Villani, Antonio Facciorusso, Francesco Bellanti, Rosanna Tamborra, Annamaria Piscazzi, Matteo Landriscina, Gianluigi Vendemiale, Gaetano Serviddio
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5172554?pdf=render